https://tuhurabio.com/tuhura-biosciences-inc-to-present-at-the-27th-annual-h-c-wainwright-global-investment-conference/ 2025-09-26T13:24:44+00:00 https://tuhurabio.com/tuhura-biosciences-inc-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update/ 2025-09-26T13:24:45+00:00 https://tuhurabio.com/tuhura-biosciences-inc-announces-inclusion-in-the-russell-3000-and-russell-2000-indexes/ 2025-09-26T13:24:45+00:00 https://tuhurabio.com/tuhura-biosciences-completes-acquisition-of-kineta/ 2025-09-26T13:24:45+00:00 https://tuhurabio.com/tuhura-biosciences-initiates-its-phase-3-accelerated-approval-trial-of-ifx-2-0-as-an-adjunctive-therapy-to-keytruda-pembrolizumab-in-first-line-treatment-for-advanced-or-metastatic-merkel-cell/ 2025-09-26T13:24:45+00:00 https://tuhurabio.com/tuhura-biosciences-inc-and-kineta-inc-stockholders-approve-proposed-merger-and-all-related-proposals/ 2025-09-26T13:24:45+00:00 https://tuhurabio.com/fda-removes-partial-clinical-hold-on-tuhura-biosciences-phase-3-accelerated-approval-trial-for-ifx-2-0-in-advanced-or-metastatic-merkel-cell-carcinoma/ 2025-09-26T13:24:46+00:00 https://tuhurabio.com/tuhura-biosciences-inc-enters-into-12-5-million-equity-financing-transaction-and-receives-additional-3-0-million-in-warrant-exercise-proceeds-to-advance-its-pipeline-of-novel-treatments-to-overcom/ 2025-09-26T13:24:46+00:00 https://tuhurabio.com/tuhura-biosciences-presents-ifx-hu2-0-trial-in-progress-poster-at-the-2025-american-society-of-clinical-oncology-annual-meeting/ 2025-09-26T13:24:46+00:00 https://tuhurabio.com/tuhura-biosciences-inc-reports-first-quarter-2025-financial-results-and-provides-a-corporate-update/ 2025-09-26T13:24:46+00:00 https://tuhurabio.com/tuhura-biosciences-inc-to-present-at-the-3rd-annual-h-c-wainwright-bioconnect-conference/ 2025-09-26T13:24:46+00:00 https://tuhurabio.com/tuhura-biosciences-inc-initiates-phase-1b-2a-study-of-ifx-hu2-0-as-an-adjunctive-therapy-to-keytruda-pembrolizumab-in-first-line-treatment-for-metastatic-merkel-cell-carcinoma-of-unknown-pri/ 2025-09-26T13:24:47+00:00 https://tuhurabio.com/tuhura-biosciences-and-kineta-present-updated-results-from-kinetas-phase-i-ii-study-of-kva12123-and-tuhuras-mechanism-of-ifx-hu2-0-responses-after-anti-pd-1-therapy-failure-in-advanced-melanoma-at/ 2025-09-26T13:24:47+00:00 https://tuhurabio.com/tuhura-biosciences-inc-announces-abstracts-accepted-for-poster-presentation-at-the-2025-aacr-annual-meeting/ 2025-09-26T13:24:47+00:00 https://tuhurabio.com/tuhura-biosciences-inc-appoints-dr-bertrand-le-bourdonnec-as-executive-vice-president-head-of-drug-discovery-early-development-and-program-management/ 2025-09-26T13:24:47+00:00 https://tuhurabio.com/tuhura-biosciences-inc-reports-financial-results-for-fiscal-year-2024-and-provides-corporate-update/ 2025-09-26T13:24:47+00:00 https://tuhurabio.com/tuhura-biosciences-inc-participates-in-the-virtual-investor-top-5-for-25-on-demand-conference/ 2025-09-26T13:24:48+00:00 https://tuhurabio.com/tuhura-biosciences-inc-enters-into-definitive-merger-agreement-to-acquire-kineta-inc/ 2025-09-26T13:24:48+00:00 https://tuhurabio.com/tuhura-biosciences-inc-to-present-at-the-37th-annual-roth-conference/ 2025-09-26T13:24:48+00:00 https://tuhurabio.com/tuhura-biosciences-inc-appoints-craig-l-tendler-m-d-former-vice-president-oncology-clinical-development-diagnostics-and-global-medical-affairs-johnson-johnson-innovative-medicine-researc/ 2025-09-26T13:24:48+00:00 https://tuhurabio.com/tuhura-biosciences-inc-nasdaq-hura-outlines-development-pathway-for-single-phase-3-accelerated-approval-registration-trial-in-first-line-treatment-of-advanced-or-metastatic-merkel-cell-carcinoma/ 2025-09-26T13:25:16+00:00 https://tuhurabio.com/tuhura-biosciences-nasdaq-hura-announces-webcast-replay-of-panel-presentation-at-the-2024-maxim-healthcare-virtual-summit-presented-by-maxim-group-llc/ 2025-09-26T13:25:16+00:00 https://tuhurabio.com/tuhura-biosciences-nasdaqhura-to-present-at-the-virtual-investor-new-to-the-street-event/ 2025-09-26T13:25:16+00:00 https://tuhurabio.com/tuhura-biosciences-enters-into-exclusivity-and-right-of-first-offer-agreement-for-kineta-inc-s-kva12123-novel-anti-vista-checkpoint-inhibitor/ 2025-09-26T13:25:16+00:00 https://tuhurabio.com/tuhura-biosciences-and-kintara-therapeutics-announce-kineta-inc-reopens-enrollment-for-vista-101-clinical-trial-evaluating-kva12123-in-patients-with-advanced-solid-tumor-cancer/ 2025-09-26T13:25:16+00:00 https://tuhurabio.com/tuhura-biosciences-completes-merger-transaction-with-kintara-therapeutics/ 2025-09-26T13:25:16+00:00 https://tuhurabio.com/tuhura-biosciences-and-kintara-therapeutics-announce-positive-results-from-phase-1b-trial-of-ifx-2-0-a-novel-personalized-cancer-vaccine-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcin/ 2025-09-26T13:25:17+00:00 https://tuhurabio.com/kintara-therapeutics-and-tuhura-biosciences-provide-update-on-recent-corporate-and-clinical-advancements-and-outline-near-term-milestones/ 2025-09-26T13:25:17+00:00 https://tuhurabio.com/tuhura-biosciences-to-present-its-ifx-2-0-personalized-cancer-vaccine-clinical-trial-results-at-the-2024-american-society-of-clinical-oncology-asco-annual-meeting/ 2025-09-26T13:25:17+00:00 https://tuhurabio.com/kintara-therapeutics-and-tuhura-biosciences-enter-into-definitive-merger-agreement/ 2025-09-26T13:25:17+00:00 https://tuhurabio.com/tuhura-biosciences-inc-appoints-dennis-yamashita-ph-d-as-chief-scientific-officer-and-head-of-discovery-research-and-early-development/ 2025-09-26T13:25:17+00:00 https://tuhurabio.com/morphogenesis-inc-announces-corporate-rebranding-to-tuhura-biosciences-inc-and-provides-a-business-overview/ 2025-09-26T13:25:18+00:00 https://tuhurabio.com/morphogenesis-inc-announces-acceptance-of-abstract-for-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting/ 2025-09-26T13:25:18+00:00 https://tuhurabio.com/morphogenesis-inc-announces-positive-results-from-phase-1b-trial-of-ifx-2-0-a-novel-personalized-cancer-vaccine-in-checkpoint-inhibitor-resistant-advanced-merkel-cell-carcinoma-mcc-and-cutaneous/ 2025-09-26T13:25:18+00:00 https://tuhurabio.com/morphogenesis-inc-to-present-at-the-virtual-investor-summer-spotlight-series/ 2025-09-26T13:25:18+00:00 https://tuhurabio.com/morphogenesis-inc-biomarker-analysis-data-from-ifx-hu2-0-in-melanoma-refractory-to-anti-pd1-based-therapies-demonstrates-ability-to-overcome-primary-resistance-to-checkpoint-inhibitors-and-trigger-a/ 2025-09-26T13:25:18+00:00 https://tuhurabio.com/morphogenesis-inc-acquires-thura-biopharmas-first-in-class-antibody-drug-conjugates-adcs-technology-designed-to-overcome-acquired-resistance-to-cancer-immunotherapy/ 2025-09-26T13:25:19+00:00 https://tuhurabio.com/morphogenesis-inc-and-cohbar-inc-announce-acceptance-of-abstract-for-poster-presentation-at-the-2023-american-society-of-clinical-oncology-asco-annual-meeting/ 2025-09-26T13:25:19+00:00